Scalable and efficient AAV production process with new Fibro chromatography technologyPublished: June 29, 2020
Thursday, 30 July 2020. 08:00 PDT; 11:00 EDT; 16:00 BST; 17:00 CEST
Production methods for adenovirus-associated virus (AAV) vectors have not kept up with the brisk pace of gene therapy development. To manufacture safe and efficacious clinical-grade virus, scalable and cost-effective production processes are needed. Towards this end, we present an efficient process for AAV production and scale-up in suspension cell culture through to purified bulk product. The process was developed by evaluating and optimizing each process step.
A novel fiber technology, Fibro, addresses the downstream bottleneck at the capture step by overcoming the diffusional and flow limitations of purification using packed-bed chromatography. Also, a new analytical assay based on surface plasmon resonance was developed for AAV quantitation.
In this webinar our panel of experts will discuss:
- How to optimize each process step of AAV production and scale-up in suspension cell culture.
- How to evaluate and optimize cell culture conditions and plasmid transfection.
- Purification methods based on filtration and chromatography, developed for AAV production.
- The advantages of Fibro chromatography in downstream processing of AAV.
Dr Laura Adamson-Small, Upstream and Analytical Development Lead, UCB Biosciences
Laura Adamson-Small has held multiple roles focused on improving AAV product quality and productivity through optimizing to viral gene expression, delivery, and upstream process design. She currently leads Upstream and Analytical Process Development for AAV vectors at UCB Biosciences in their Early Solutions team. She started her career in AAV supporting multiple aspects of AAV development at the University of Florida Powell Gene Therapy Center. Prior to joining UCB, she previously held led a team focusing on upstream process development and packaging plasmid design improvements for AAV vectors at Homology Medicines.
Dr Mats Lundgren, Customer Applications Director, Cytiva
Mats has more than 25 years of experience in the field of biotechnology. He holds a PhD in Immunology, Cell and Molecular Biology from the Karolinska Institute, Stockholm, Sweden and extensive post-doc training at the MRC Clinical Sciences Centre, Imperial College School of Medicine in London, UK. In his industrial career Mats has had positions as scientist, team manager and Vice President at Pharmacia, AstraZeneca and smaller biotech companies. In his previous function, Mats was managing both the Cell line and Upstream Process Development teams at a major biotech company. In his current role, Mats works across different viral vector and vaccine application projects as well as general upstream topics, focusing on customer support, applicability of new technologies and manufacturing solutions.
Dr Peter Guterstam, Product Manager, Next Generation Resins & Technologies, Cytiva
Peter is Global Product Manager at Cytiva with responsibility for products tailored for downstream processing of Advanced Therapy Medicinal Products. He is based in Uppsala, Sweden. Peter earned is PhD in Neurochemistry from Stockholm University in 2009. He has been with GE since 2003, primarily working in various roles associated with oligonucleotide synthesis and purification. Since GE’s acquisition of Puridify, Peter has the business responsibility to develop products based on the Fibro technology to complement Cytiva’s portfolio of chromatography resins and to develop it further to generate tailored solutions for the manufacture of Advanced Therapy Medicinal Products.